Rheumatoid arthritis (RA) patients with chronic kidney failure are intolerant to most disease-modifying antirheumatic drugs (DMARDs) and NSAIDs due to their potential toxicities. Although the tumor necrosis factor (TNF) inhibitors have emerged as a highly effective treatment for RA, their safety and efficacy in RA patients with chronic kidney failure have not been well reported. We retrospectively evaluated the safety and efficacy of etanercept treatment in RA patients with chronic kidney failure. We describe three RA patients with chronic kidney failure who had been treated with DMARDs, steroids and NSAIDs, but were discontinued from these classical agents due to several side effects and nephrotoxicity. The patients were treated with 25 mg of etanercept once or twice a week. We evaluated disease activity and used decreasing renal function and increasing number of infections to monitor safety. All three patients improved after starting etanercept treatment and their steroid requirements were decreased. Linear relationships between Modification of Diet in Renal Disease study equation (MDRD) glomerular filtration rate (GFR) and time were observed. Thus, in all patients, the changes in GFR did not represent superimposed acute drug toxicity, but rather chronic progressive renal failure. These cases show that etanercept may be a safe and effective treatment option for RA patients with chronic kidney failure.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00296-009-1108-z | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Polysomnographic titration of non-invasive ventilation in motor neurone disease (3TLA): study protocol for a randomised controlled trial.
Trials
January 2025
Department of Physiotherapy, Melbourne School of Health Science, University of Melbourne, Melbourne, Australia.
Background: Non-invasive ventilation (NIV) uses positive pressure to assist people with respiratory muscle weakness or severe respiratory compromise to breathe. Most people use this treatment during sleep when breathing is most susceptible to instability. The benefits of using NIV in motor neurone disease (MND) are well-established.
View Article and Find Full Text PDFMesenchymal stem cell therapy as a game-changer in liver diseases: review of current clinical trials.
Stem Cell Res Ther
January 2025
School of Medical Laboratory Science and Biotechnology, College of Medical Science and Technology, Taipei Medical University, 10F., Teaching & Research Building, Shuang-Ho Campus, No. 301, Yuantong Rd., Zhonghe Dist., Taipei, 235, Taiwan.
Chronic liver diseases, including cirrhosis and liver failure, remain formidable challenges due to their complex progression and limited therapeutic options. Mesenchymal stem cell (MSC) therapy has emerged as a game-changing approach, leveraging its potent immunomodulatory, anti-fibrotic, and regenerative capabilities, along with the ability to transdifferentiate into hepatocytes. This review delves into the latest advances in MSC-based treatments for chronic and end-stage liver diseases, as highlighted in current clinical trials.
View Article and Find Full Text PDFImpact of multifaceted interventions on pressure injury prevention: a systematic review.
BMC Nurs
January 2025
Department of Adult Health Nursing, College of Health Sciences, Arsi University, Asella, Ethiopia.
Background: Pressure injuries are a significant concern in healthcare settings, leading to increased morbidity, healthcare costs, and patient suffering. This systematic review aims to evaluate the impact of multifaceted interventions on the prevention of Pressure injuries and improvements in nursing practices.
Methods: A systematic search was conducted following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines across multiple databases, including studies from Google Scholar (332), Science Direct (14), grey literature sources (45), PubMed (0), Cochrane Library (437), and Hinari (322).
Can integrated care interventions strengthen primary care and improve outcomes for patients with chronic diseases? A systematic review and meta-analysis.
Health Res Policy Syst
January 2025
China Center for Health Development Studies, Peking University, 38 Xueyuan Rd, Haidian District, Beijing, China.
Background: An increasing number of people live with chronic disease or multi-morbidity. Current consensus is that their care requires an integrated model bringing different professionals together to provide person-centred care. Although primary care has a central role in managing chronic disease, and integration may be important in strengthening this role, previous research has shown insufficient attention to the relationships between primary care and integration.
View Article and Find Full Text PDFStakeholder perspectives on facilitators and barriers to implementing a zero-dollar copay program for chronic conditions study.
Health Res Policy Syst
January 2025
Department of Maternal and Child Health, University of North Carolina Chapel Hill School of Global Public Health, Chapel Hill, United States of America.
Background: Type 2 diabetes mellitus (T2D) remains a pressing public health concern. Despite advancements in antidiabetic medications, suboptimal medication adherence persists among many individuals with T2D, often due to the high cost of medications. To combat this issue, Blue Cross and Blue Shield of Louisiana (Blue Cross) introduced the $0 Drug Copay (ZDC) program, providing $0 copays for select drugs.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!